CALQUENCE vs IMKELDI

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 21, 2026·How we rate

Possible drug interaction. CALQUENCE and IMKELDI are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	CALQUENCE	IMKELDI
Rating	70/100	New
Pharmacy pays	—	~$25.80 /30
Type	RX	RX
Active ingredient	ACALABRUTINIB	IMATINIB MESYLATE
Manufacturer	Astrazeneca	Shorla Oncology
Dosage forms	Capsule, Tablet	Solution
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	None	None
Treats	Mantle-Cell Lymphoma	Lymphoid Leukemia, Myeloid Leukemia, Hypereosinophilic Syndrome

calquence imkeldi

Rating

70/100

New

Pharmacy pays

—

~$25.80 /30

Type

Active ingredient

ACALABRUTINIB

IMATINIB MESYLATE

Manufacturer

Astrazeneca

Shorla Oncology

Dosage forms

Capsule, Tablet

Solution

Drug class

Kinase Inhibitor

Boxed warning

None

Treats

Mantle-Cell Lymphoma

Lymphoid Leukemia, Myeloid Leukemia, Hypereosinophilic Syndrome

Frequently asked questions

What is the difference between Calquence and Imkeldi?

Calquence contains Acalabrutinib, while Imkeldi contains Imatinib Mesylate — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.